The Impact of Population-Based Disease Management Services on Health Care Utilisation and Costs: Results of the CAPICHe Trial.
Adolescent
Adult
Aged
Aged, 80 and over
Australia
/ epidemiology
Chronic Disease
/ economics
Cost-Benefit Analysis
Disease Management
Female
Follow-Up Studies
Humans
Insurance, Health
/ statistics & numerical data
Intention to Treat Analysis
/ methods
Male
Middle Aged
Morbidity
/ trends
Patient Acceptance of Health Care
/ statistics & numerical data
Quality of Life
Young Adult
costs
disease management
insurance
private healthcare
Journal
Journal of general internal medicine
ISSN: 1525-1497
Titre abrégé: J Gen Intern Med
Pays: United States
ID NLM: 8605834
Informations de publication
Date de publication:
01 2019
01 2019
Historique:
received:
26
12
2017
accepted:
12
09
2018
revised:
06
07
2018
pubmed:
29
9
2018
medline:
21
4
2020
entrez:
29
9
2018
Statut:
ppublish
Résumé
Disease management programmes may improve quality of care, improve health outcomes and potentially reduce total healthcare costs. To date, only one very large population-based study has been undertaken and indicated reductions in hospital admissions > 10%. We sought to confirm the effectiveness of population-based disease management programmes. The objective of this study was to evaluate the relative impact on healthcare utilisation and cost of participants the Costs to Australian Private Insurance - Coaching Health (CAPICHe) trial. Parallel-group randomised controlled trial, intention-to-treat analysis SETTING: Australian population PARTICIPANTS: Forty-four thousand four hundred eighteen individuals (18-90 years of age) with private health insurance and diagnosis of heart failure, chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), diabetes, or low back pain, with predicted high cost claims for the following 12 months. Health coaching for disease management from Bupa Health Dialog, vs Usual Care. Total cost of claims per member to the private health insurer 1 year post-randomisation for hospital admissions, including same-day, medical and prostheses hospital claims, excluding any maternity costs. Analysis was based on the intent-to-treat population. Estimated total cost 1 year post-randomisation was not significantly different (means: intervention group A$4934; 95% CI A$4823-A$5045 vs control group A$4868; 95% CI A$4680-A$5058; p = 0.524). However, the intervention group had significantly lower same-day admission costs (A$468; 95% CI A$454-A$482 vs A$508; 95% CI A$484-A$533; p = 0.002) and fewer same-day admissions per 1000 person-years (intervention group, 530; 95% CI 508-552 vs control group, 614; 95% CI 571-657; p = 0.002). Subgroup analyses indicated that the intervention group had significantly fewer admissions for patients with COPD and fewer same-day admissions for patients with diabetes. Chronic disease health coaching was not effective to reduce the total cost after 12 months of follow-up for higher risk individuals with a chronic condition. Statistically significant changes were found with fewer same-day admissions; however, these did not translate into cost savings from a private health insurance perspective.
Sections du résumé
BACKGROUND
Disease management programmes may improve quality of care, improve health outcomes and potentially reduce total healthcare costs. To date, only one very large population-based study has been undertaken and indicated reductions in hospital admissions > 10%.
OBJECTIVE
We sought to confirm the effectiveness of population-based disease management programmes. The objective of this study was to evaluate the relative impact on healthcare utilisation and cost of participants the Costs to Australian Private Insurance - Coaching Health (CAPICHe) trial.
DESIGN
Parallel-group randomised controlled trial, intention-to-treat analysis SETTING: Australian population PARTICIPANTS: Forty-four thousand four hundred eighteen individuals (18-90 years of age) with private health insurance and diagnosis of heart failure, chronic obstructive pulmonary disease (COPD), coronary artery disease (CAD), diabetes, or low back pain, with predicted high cost claims for the following 12 months.
INTERVENTION
Health coaching for disease management from Bupa Health Dialog, vs Usual Care.
MAIN OUTCOME MEASURES
Total cost of claims per member to the private health insurer 1 year post-randomisation for hospital admissions, including same-day, medical and prostheses hospital claims, excluding any maternity costs. Analysis was based on the intent-to-treat population.
RESULTS
Estimated total cost 1 year post-randomisation was not significantly different (means: intervention group A$4934; 95% CI A$4823-A$5045 vs control group A$4868; 95% CI A$4680-A$5058; p = 0.524). However, the intervention group had significantly lower same-day admission costs (A$468; 95% CI A$454-A$482 vs A$508; 95% CI A$484-A$533; p = 0.002) and fewer same-day admissions per 1000 person-years (intervention group, 530; 95% CI 508-552 vs control group, 614; 95% CI 571-657; p = 0.002). Subgroup analyses indicated that the intervention group had significantly fewer admissions for patients with COPD and fewer same-day admissions for patients with diabetes.
CONCLUSIONS
Chronic disease health coaching was not effective to reduce the total cost after 12 months of follow-up for higher risk individuals with a chronic condition. Statistically significant changes were found with fewer same-day admissions; however, these did not translate into cost savings from a private health insurance perspective.
Identifiants
pubmed: 30264259
doi: 10.1007/s11606-018-4682-5
pii: 10.1007/s11606-018-4682-5
pmc: PMC6318195
doi:
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
41-48Commentaires et corrections
Type : CommentIn
Références
Health Econ. 2011 Aug;20(8):897-916
pubmed: 20799344
Diabetes Educ. 2010 Jul-Aug;36(4):629-39
pubmed: 20534872
Arab J Gastroenterol. 2013 Dec;14(4):165-8
pubmed: 24433646
Heart Lung Circ. 2015 May;24(5):471-9
pubmed: 25705032
Biometrics. 2009 Jun;65(2):640-9
pubmed: 18510650
Stat Med. 2012 Nov 30;31(27):3393-405
pubmed: 22714868
JAMA. 1997 Nov 26;278(20):1687-92
pubmed: 9388089
Stat Med. 2015 Nov 20;34(26):3444-60
pubmed: 26032906
West J Nurs Res. 2014 Oct;36(9):1052-73
pubmed: 24569698
BMJ. 2013 Sep 18;347:f5272
pubmed: 24048296
Health Aff (Millwood). 2007 Nov-Dec;26(6):1683-91
pubmed: 17978387
BMC Health Serv Res. 2012 Jun 10;12:147
pubmed: 22682298
Diabetes Res Clin Pract. 2014 Apr;104(1):103-11
pubmed: 24503043
BMC Public Health. 2012 Aug 03;12:602
pubmed: 22857017
BMC Cardiovasc Disord. 2013 May 01;13:33
pubmed: 23634982
BMJ. 2000 Feb 26;320(7234):563-6
pubmed: 10688566
BMJ. 2010 May 04;340:c2073
pubmed: 20442226
BMC Public Health. 2012 Feb 10;12:114
pubmed: 22325668
Am J Prev Med. 2007 May;32(5):419-34
pubmed: 17478269
Int J Behav Med. 2013 Sep;20(3):413-24
pubmed: 23012159
N Engl J Med. 2010 Sep 23;363(13):1245-55
pubmed: 20860506
J Gen Intern Med. 2009 May;24(5):649-55
pubmed: 19308336